NICE机器人辅助骨科手术早期价值评估综述
该综述总结了英国NICE对机器人辅助骨科手术(UKA、TKA、THA)的早期价值评估,基于28项研究和两个注册库发现机器人在主要结局上不劣于传统方法且植入物对线更优,但短期PROM改善未达临床意义阈值;NICE有条件推荐六种机器人平台在三年证据生成期内使用。
要点
- 机器人辅助关节置换在PROMs、并发症、住院时间和翻修方面不劣于传统方法,且植入物对线更优。
- 短期PROMs有适度改善,但多数差异低于目前定义的临床意义阈值。
- NICE有条件推荐六种机器人平台,需三年内每年报告并遵守监管标准。
核心结论
- 机器人辅助关节置换术具有技术优势,但明确的临床和经济获益尚未证实。
研究设计与样本
- 综述总结了NICE开展的早期价值评估(EVA),包括文献回顾、证据缺口分析和证据生成计划。
主要发现
- 来自28项研究和两个注册库的证据表明,机器人辅助手术在PROMs、并发症、住院时间和翻修等关键结局上不劣于传统方法。
- 机器人辅助手术与植入物对线更优相关。
- 短期PROMs显示适度改善,但大多数差异低于目前定义的临床意义阈值。
- 翻修数据随访有限,外科医生的人体工学获益不确定。
- 经济评估提示潜在成本效益,尤其对THA,但关于效用、资源使用、手术量和植入物成本的假设引入了大量不确定性。
关键数值与推荐
- NICE有条件推荐六种机器人平台(ApolloKnee、CORI、Mako、ROSA、SkyWalker、VELYS)在三年证据生成期内使用,要求年度报告并遵守监管标准。
临床怎么用
- 外科医生、医疗系统和行业合作伙伴需协作在三年内提供所需证据。
- 英国机器人注册库可能比单个中心更快地解决证据缺口。
局限性
- 证据缺口包括长期翻修率、健康相关生活质量结局、生产力、亚组效应、手术团队获益和学习曲线。
- 翻修数据随访有限,外科医生的人体工学获益不确定。
- 经济评估中的假设引入了大量不确定性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Robotic-assisted systems are being increasingly integrated into orthopaedic surgery, offering potential improvements in precision, reproducibility, and patient-reported outcome measures (PROMs) for unicompartmental knee arthroplasty (UKA), total knee arthroplasty (TKA), and total hip arthroplasty (THA). A review and summary of the early value assessment (EVA) undertaken by the National Institute for Health and Care Excellence (NICE) to evaluate the clinical effectiveness, cost-effectiveness, and implementation considerations of these technologies is presented. The EVA includes a review of the literature, an evidence gap analysis, and an evidence generation plan. Evidence from 28 studies and two registries suggested that robotic-assisted surgery was noninferior to conventional approaches in key outcomes, including PROMs, complications, hospital stay, and revisions, but it was associated with enhanced implant alignment. Short-term PROMs showed modest improvements, although most differences fell below currently defined clinically meaningful thresholds. Revision data were limited in follow-up, and ergonomic benefits for surgeons were uncertain. Economic evaluations suggested potential cost-effectiveness, particularly for THA, but assumptions regarding utilities, resource use, procedure volume, and implant costs introduced substantial uncertainty. The EVA highlighted the importance of training, equitable access, and national coordination for implementation. Evidence gaps were identified in long-term revision rates, health-related quality of life outcomes, productivity, sub-group effects, surgical team benefits, and learning curves. NICE recommended conditional adoption of six robotic platforms (ApolloKnee (Corin, UK), CORI (Smith & Nephew, UK), Mako (Stryker, USA), ROSA (Zimmer Biomet, USA), SkyWalker (MicroPort, China), and VELYS (DePuy Synthes, USA)) over a three-year evidence generation period, requiring annual reporting and adherence to regulatory standards. While robotic-assisted arthroplasty offers technical advantages, definitive clinical and economic benefits remain unproven. Surgeons, healthcare systems, and industry partners will need to work collaboratively to provide the required evidence in the next three years. A UK robotic registry could help address the evidence gaps more rapidly than individual centres by capturing large-scale national data.
引用
- Clement ND, Haddad FS. A review and summary of the National Institute for Health and Care Excellence early value assessment of robotic-assisted surgery for orthopaedic procedures. Bone Joint J. 2026. PMID: 41619793. doi:10.1302/0301-620X.108B2.BJJ-2025-1438
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。